Here, we showed that Ezh2 inhibition by DZNEP could reduce Doc-induced gene expression of cancer stem cell markers (Nanog, CD44 and Sox2), supporting the notion that Ezh2 acts on these genes independent of PRC2 complex. Here, CD44 is linked to cancer.